[生理节奏和心力衰竭:希望还是作?]
Victoria Johnson1, Carlos Antepara2, Reza Wakili3,4
1Universitäres Herzzentrum, ZIM III, Abteilung für Kardiologie, Universitätsmedizin Frankfurt, Theodor-Stern-Kai 7, 60596, Frankfurt, Deutschland. Victoria.johnson@herz-frankfurt.de.
Herzschrittmachertherapie & Elektrophysiologie
|February 18, 2025
概括
新的节奏技术,如左束枝区域节奏 (LBBAP),为心力衰竭患者提供了传统心脏再同步治疗 (CRT) 的替代方案. 在改善结果方面,LBBAP显得有前途,特别是在心脏起器诱导的心肌病症的情况下.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 心脏衰竭管理的管理
背景情况:
- 标准的心力衰竭治疗包括四大支柱药物治疗.
- 生理刺激有利于心力衰竭和左捆支部阻塞的患者或需要心器起器的患者.
- 心脏再同步疗法 (CRT) 是心力衰竭的既定治疗方法,具有减少喷射率 (HFrEF) 和左捆支部阻断.
研究的目的:
- 探索新的节奏技术作为CRT的替代品.
- 评估左束枝区域节奏 (LBBAP) 在心力衰竭患者的疗效.
- 为了应对心脏起器诱导的心肌病的挑战.
主要方法:
- 研究直接导电系统刺激技术.
- 专注于左捆分支区域步调 (LBBAP) 作为主要方法.
- 将LBBAP结果与现有疗法进行比较.
主要成果:
- 新的刺激方法可以达到类似于CRT的临床结果.
- 左捆支部区域节奏 (LBBAP) 目前是研究最多的新兴刺激技术.
- 对于心脏起器诱导的心肌病,LBBAP是一个有前途的解决方案.
结论:
- 直接导电系统刺激,特别是LBBAP,正在成为CRT的可行替代品.
- 在改善心力衰竭管理方面,LBBAP具有显著的潜力.
- 对于患有特定节奏相关并发症的患者来说,LBBAP是一种有希望的进步.
更多相关视频
相关概念视频
Heart Failure Drugs: Inotropic Agents
500
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
500
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: β-Blockers
308
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
308
Pulse rhythm
754
Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
754
Regulation of Heart Rates
1.6K
The regulation of heart rate is a complex process controlled by the autonomic nervous system (ANS), hormonal influences, and intrinsic cardiac mechanisms. The ANS has two main components: the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS).
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
371
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371


